$0.83
7.37%
Nasdaq, Fri, Dec 27 2024
ISIN
US44984F3029
Symbol
INVO

INVO Bioscience Inc Stock price

$0.83
-0.11 11.48% 1M
-0.04 4.75% 6M
-0.52 38.69% YTD
-0.53 39.14% 1Y
-71.17 98.85% 3Y
-143.17 99.43% 5Y
-159.17 99.48% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.07 7.37%
ISIN
US44984F3029
Symbol
INVO

Key metrics

Market capitalization $3.71m
Enterprise Value $15.66m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.71
P/S ratio (TTM) P/S ratio 0.64
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth 390.03%
Revenue (TTM) Revenue $5.77m
EBIT (operating result TTM) EBIT $-5.24m
Free Cash Flow (TTM) Free Cash Flow $-3.97m
Cash position $940.00k
EPS (TTM) EPS $-2.54
Short interest 0.05%
Show more

Is INVO Bioscience Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

INVO Bioscience Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast INVO Bioscience Inc:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast INVO Bioscience Inc:

Hold
100%

Financial data from INVO Bioscience Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
5.77 5.77
389% 389%
100%
- Direct Costs 3.80 3.80
435% 435%
66%
1.97 1.97
328% 328%
34%
- Selling and Administrative Expenses 6.58 6.58
30% 30%
114%
- Research and Development Expense 0.01 0.01
98% 98%
0%
-4.62 -4.62
51% 51%
-80%
- Depreciation and Amortization 0.62 0.62
148% 148%
11%
EBIT (Operating Income) EBIT -5.24 -5.24
45% 45%
-91%
Net Profit -7.08 -7.08
30% 30%
-123%

In millions USD.

Don't miss a Thing! We will send you all news about INVO Bioscience Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

INVO Bioscience Inc Stock News

Neutral
GlobeNewsWire
2 months ago
SARASOTA, Fla. and MIAMI, Oct. 24, 2024 (GLOBE NEWSWIRE) -- NAYA Biosciences (“NAYA”) (NASDAQ: NAYA), a life science portfolio company dedicated to bringing breakthrough treatments to patients in oncology, autoimmune diseases, and fertility, today announced an update regarding its clinic trial plans. The Company received regulatory approval from the Israeli Ministry of Health in July 2024 and s...
Neutral
GlobeNewsWire
2 months ago
SARASOTA, Fla. and MIAMI, Oct. 21, 2024 (GLOBE NEWSWIRE) -- INVO Biosciences (Nasdaq: INVO), a company focused on expanding its portfolio of clinical and commercial-stage assets in fertility, oncology, and autoimmune diseases through the merger of INVO Biosciences and NAYA Biosciences, today confirmed it has changed its corporate name to NAYA Biosciences Inc. and will begin trading under the ne...
Neutral
GlobeNewsWire
3 months ago
Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseases Combined company to expand portfolio of clinical & commercial-stage assets in fertility, oncology, and autoimmune diseases

Company Profile

INVO BioScience, Inc. focuses on the creation of treatment options for patients diagnosed with infertility. It offers a patented medical device that is used for infertility treatment under the name INVOcell. The company was founded by Kathleen Karloff and Claude Ranoux on January 5, 2007 and is headquartered in Medford, MA.

Head office United States
CEO Steven Shum
Employees 30
Founded 2007
Website www.nayabiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today